Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage IV melanoma~  * Mucosal or ocular melanoma allowed~* Clinically evaluable disease~* HLA-A\*0201 positive~PATIENT CHARACTERISTICS:~Age:~* 16 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 6 months~Hematopoietic:~* WBC at least 2,500/mm\^3~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10 g/dL~* Hematocrit at least 30%~Hepatic:~* AST no greater than 3 times upper limit of normal (ULN)~* Bilirubin no greater than ULN (less than 3.0 mg/dL in patients with Gilbert's syndrome)~* Hepatitis B surface antigen negative~* Hepatitis C antibody nonreactive~Renal:~* Creatinine less than 2.0 mg/dL~Immunologic:~* Antinuclear antibody negative~* Thyroglobulin antibody normal~* Rheumatoid factor normal~* HIV negative~* No prior autoimmune disease (including uveitis and autoimmune inflammatory eye disease)~* No active infection~* No hypersensitivity to Montanide ISA-51~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix~* No other underlying medical condition that would preclude study therapy~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 3 weeks since prior immunotherapy for melanoma and recovered~* No prior gp100 peptides~* No prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody~Chemotherapy:~* At least 3 weeks since prior chemotherapy for melanoma and recovered~* No concurrent chemotherapy~Endocrine therapy:~* At least 3 weeks since prior hormonal therapy for melanoma and recovered~* At least 4 weeks since prior systemic or topical corticosteroids~* No concurrent topical or systemic corticosteroids~Radiotherapy:~* At least 3 weeks since prior radiotherapy for melanoma and recovered~Surgery:~* Not specified~Other:~* No other concurrent immunosuppressive agents (e.g., cyclosporine and its analog)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).